一、临床药理学与治疗学 (2026年第119卷第3期)
Clinical Pharmacology & Therapeutics 
March 2026 - Volume 119 - Issue 3（2026年3月第119卷第3期）
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2026/119/2

Editorial（社论）
1.个体化药物治疗：连接数据科学与临床现实
Tailoring Drug Therapy: Bridging Data Science and Clinical Reality
Karen Rowland Yeo*
Perspective（观点）
Letter to the Editor（读者来信）
2.基于保守PBPK模型与临床数据支持UGT1A1抑制对阿扎那韦相关胆红素升高的次要贡献
Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data
Jin Dong*
Reply（回复）
3.对“基于保守PBPK模型与临床数据支持UGT1A1抑制对阿扎那韦相关胆红素升高的次要贡献”一文的回复
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data"
John O. Miners*
Letter to the Editor（读者来信）
4.关于RWE评估FRAME框架中的选择与分析透明度
On Selection and Analytical Transparency in the FRAME Framework for RWE Evaluation
Jörg Tomeczkowski*
Reply（回复）
5.对“关于RWE评估FRAME框架中的选择与分析透明度”一文的回复
Reply to "On Selection and Analytical Transparency in the FRAME Framework for RWE Evaluation"
Gianmario Candore*
White Paper（白皮书）
6.人体质量平衡研究中的引导式样本合并：推荐策略决策框架
Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework
Filip Cuyckens*, Wenying Li*
Review（综述）
Systematic Review（系统综述）
7.类风湿关节炎患者使用JAK抑制剂相关的恶性肿瘤与主要心血管不良事件风险：一项荟萃分析
Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta-Analysis
Hongmei Duan, Tianlong Jiang*
Tutorial（教程）
8.药物诱导肾损伤的生物标志物：在临床试验中的应用及对药物开发影响的近期案例
Biomarkers of Drug-Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
Tanja S. Zabka, Nicholas M. P. King*
Research（研究）
Article（文章）
9.整合群体药代动力学、药效学与安全性分析以指导ATR抑制剂Tuvusertib临床开发中的剂量选择
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
Jatinder Kaur Mukker*
10.莫莫替尼、其活性代谢物（M21）及总活性成分在骨髓纤维化患者中的群体药代动力学与暴露-效应分析
Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
Benjamin Rich, Georgios Vlasakakis*
11.应用生理药代动力学模型指导Mezigdomide在I期药物相互作用研究中的剂量选择
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
Joseph Burnett, Allison Gaudy*
12.阿达木单抗生物类似药转换的药物存留率与耐受性队列研究：药物本身性质确实重要
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy C.D. Peeters*
13.抗体药物偶联物相关的呼吸系统疾病：法国及WHO药物警戒数据库联合分析
Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
Victor Mirleau, Julien Mahé*
14.基于胱抑素C估算的肾小球滤过率比基于肌酐估算的能更好预测异基因干细胞移植患者的万古霉素肾脏清除率
Cystatin C-based eGFR better predicts renal vancomycin clearance than creatinine-based eGFR in patients with allogeneic stem cell transplantation
Eva-Maria A. Wansing*
15.突破障碍：皮内脂多糖激发作为健康志愿者血管渗漏可控诱导体内模型的表征
Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers
Marella Cornelia Elizabeth van Ruissen, Matthijs Moerland*
16.老年患者接受减量依度沙班方案的真实世界血药浓度研究
Real-World Edoxaban Concentrations in Older Patients Receiving Reduced-Dose Regimens
Sung-Chun Tang, Shin-Yi Lin*

二、药理学评论 
Pharmacological Reviews
March 2026 - Volume 78 - Issue 2 （2026年3月第78卷第3期）

https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/229/suppl/C

Review Articles（综述文章）
1.安慰剂镇痛的神经药理学基础：慢性疼痛背景下的机制与临床应用
The neuropharmacological basis of placebo analgesia: Mechanisms and clinical applications in the context of chronic pain
Damien C. Boorman*
2.基于行为经济学和药物自我给药的药物滥用潜力临床前测试：提高药物分级监管分辨率的策略
Preclinical abuse potential testing using behavioral economics and drug self-administration demand-curve analysis: A strategy to improve resolution of drug stratification for regulatory control
Matthew L. Banks*
3.家族性高胆固醇血症的病理生理学到治疗：现有与新兴的药物疗法
From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies
Arrigo F.G. Cicero, Amirhossein Sahebkar*
4.溶质载体转运蛋白在化疗药物生物分布与毒性中的作用
Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs
Mike Boeckman, Alex Sparreboom*
5.血脑屏障的药理学调控：机制、治疗策略与新兴技术
Pharmacological modulation of the blood-brain barrier: Mechanisms, therapeutic strategies, and emerging technologies
Iosif Pediaditakis*
6.代谢性疾病中胆汁酸合成与修饰酶的药理学与治疗学
Pharmacology and therapeutics of bile acid synthesis and modification enzymes in metabolic diseases
Lili Ding, Lihua Jin*
7.多物质使用在兴奋剂使用障碍发生、维持与治疗中的作用
The role of polysubstance use in the development, maintenance, and treatment of stimulant use disorders
Mia I. Rough*
8.COVID-19、长新冠与神经退行性疾病之间的关联：鞘糖脂的作用
Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids
Michael Spedding*
9.从神经免疫环路到慢性瘙痒的靶向治疗
From neuroimmune circuits to targeted therapy of chronic pruritus
Torben Ramcke*
10.肝脏疾病中的肠道微生物组与胆汁酸代谢：机制、临床意义与治疗机遇
Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities
Huiping Zhou*
11.药物基因组学的发展格局：当前成就与未来方向
The evolving landscape of pharmacogenomics: Current achievements and future directions
Volker M. Lauschke*, Magnus Ingelman-Sundberg*
12.用于药物递送的碳点：对其纳米药理学潜力的见解
Carbon dots for drug delivery: Insights into their potential in nanopharmacology
Daniela Iannazzo, Alessandra Bitto*

三、先进药物输送评论（2026年第230卷） 
Advanced Drug Delivery Reviews
March 2026 - Volume 230（2026年3月第230卷）

https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/229/suppl/C

Editorial（社论）
1.社论：基于超声的新型精准治疗与可视化策略
Editorial: Novel ultrasound-based strategies for precision therapeutics and visualization
Xinwu Cui*, Xiaoyuan Chen*
Review article（综述文章）
2.干细胞和体细胞中生成胰岛素分泌β细胞的基因工程方法
Genetic engineering approaches in stem and somatic cells for the generation of insulin-producing β-cells
Abiramy Jeyagaran, Katja Schenke-Layland*
3.PROTACs的合理修饰实现肿瘤选择性蛋白降解
Rational modification of PROTACs for tumor-selective protein degradation
Zhongliang Fu, Jinghong Li*
4.利用靶向蛋白降解增强癌症免疫治疗：从分子机制到递送策略
Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategies
Ye Liu, Jun Wang*
5.生物制品-器械组合：实现眼后段疾病的长期治疗
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Shuqian Zhu, Feng Qian*
6.治疗性气体作为口腔疾病的新兴治疗方法
Therapeutic gases as emerging treatments for oral diseases
Ann Badia, Tagbo H.R. Niepa*
7.靶向蛋白降解中的共价化学
Covalent chemistry in targeted protein degradation
Jing Tan, Shiqun Shao*
8.蛋白治疗药物中亚可见颗粒的光学成像与光谱表征
Optical imaging and spectroscopic characterization of subvisible particles in protein therapeutics
Brian S. Wong, Dan Fu*
9.核酸递送技术在血液恶性肿瘤治疗中的应用
Technology for Nucleic Acid Delivery in the Treatment of Hematological Malignancies
Saba Abbasi Dezfouli, Hasan Uludağ*
10.预测优势：药物产品开发中的建模与模拟
The predictive edge: modeling and simulation in drug product development
Sanjay Konagurthu*
11.用于治疗中枢神经系统损伤的医用气体
Medicinal gases for treating central nervous system injuries
Rebecca I. Sienel, Nikolaus Plesnila*
12.数据科学方法与创新药物递送技术的协同效应
Synergies between data science methods and innovative drug delivery technologies
David A. Winkler*
13.改善寡核苷酸治疗药物向中枢神经系统递送的生物偶联物
Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system
Hye Jin Lee*

四、药理学发展趋势 (2026年第47卷第3期)
Trends in Pharmacological Sciences

March 2026 - Volume 47 - Issue 3（2026年3月第47卷第3期）
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(25)X0014-6

TrendsTalk（趋势对话）
1.2026年3月期 首轮作者风采
March 2026 issue first authors
Morgan M. Barnes*, Taoqian Zhao*, Wanlin Ye*, Mengying Liu*, Simon Hasinger*, Nadia B. Pedersen*, Rajan Thapa*
Forum（论坛）
2.靶向FLT3治疗急性髓系白血病的范式演变
Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy
Rajan Thapa, Keshav Raj Paudel*
Reviews（综述）
3.棕榈酰蛋白硫酯酶-1在健康与疾病中的作用
Palmitoyl-protein thioesterase-1 in health and disease
Morgan Barnes, Sean Ekins*
4.靶向α疗法的演进与革命：用于临床的新型核素
Targeted alpha therapy (r)evolution: emerging nuclides for clinical applications
Nadia B. Pedersen, Umberto Maria Battisti*
5.利用构象集合进行变构药物发现
Leveraging conformational ensembles in allosteric drug discovery
Ruth Nussinov*
6.β-arrestins与疾病相关变异：靶向调控的机遇
β-Arrestins and disease-linked variants: opportunities for targeted modulation
Simon Hasinger, Christian W. Gruber*
7.利用先进递送系统靶向代谢脆弱性
Targeting metabolic vulnerabilities with advanced delivery systems
Wanlin Ye, Zhaoting Li*
8.超越脂质：非诺贝特在糖尿病视网膜病变与肾病中的应用
Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
Mengying Liu, Xiaomeng Wang*
Drug of the Month（本月焦点新药）
9.Attruby用于治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）
Attruby for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
Taoqian Zhao, Steven H. Liang*

五、药理学与治疗学 (2026年第279卷)
Pharmacology & Therapeutics

March 2026 - Volume 279 （2026年3月第279卷）
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/278/suppl/C

Review article（综述文章）
1.SGLT2抑制剂：是否具有抗心律失常特性？
SGLT2 inhibitors: Do they have antiarrhythmic properties?
Ricardo Caballero, Juan Tamargo*
2.靶向新型信号通路调控阻塞性肺疾病慢性炎症的治疗潜力
Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders
Dan Li, Martina Schmidt*
3.挖掘海洋化合物在对抗神经退行性疾病中未被开发的潜力
A dive into the untapped potential of marine compounds in counteracting neurodegeneration
Inês Costa, Renata Silva*

六、药物 (2026年第86卷第3期)
Drugs

March 2026 - Volume 86 - Issue 3（2026年3月第86卷第3期）
https://link.springer.com/journal/40265/volumes-and-issues/86-2

Leading Article（引领性文章）
1.纳米胶囊西罗莫司联合培加德凯酶（NASP）治疗难治性痛风：现状与未来方向
Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future Directions
Herbert S. B. Baraf*
2.类风湿关节炎相关间质性肺病治疗的进展与挑战：从发病机制到治疗机遇
Developments and Challenges in Treating Rheumatoid Arthritis-Related Interstitial Lung Disease: From Pathogenesis to Treatment Opportunities
Marco Sebastiani, Elisabeth Bendstrup*
Review Article（综述文章）
3.IgA肾病中的代谢检查点：从发病机制到精准医学
Metabolic Checkpoints in IgA Nephropathy: From Pathogenesis to Precision Medicine
Huixia Liu, Jing Xiong*
4.妊娠期肥胖的药理学管理：当前与新兴疗法综述
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies
Penelope Fotheringham, David Simmons*
5.EGFR突变转移性非小细胞肺癌的一线治疗与治疗序贯：哪类患者适合哪种方案？
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Pamela Abdayem, David Planchard*
Systematic Review（系统综述）
6.已上市药物重定位治疗骨关节炎的潜力：临床研究范围综述
The Potential of Authorised Drugs to be Repurposed for the Treatment of Osteoarthritis: A Scoping Review of Clinical Studies
Michelle W. J. Heijman*
AdisInsight Report（新药速递）
7.首款获批：依拉米肽
Elamipretide: First Approval
Matt Shirley
8.首款获批：利扎布替尼
Rilzabrutinib: First Approval
Arnold Lee
9.首款获批：泽普鲁美托司他
Zeprumetostat: First Approval
Susan J. Keam
10.首款获批：宗格替尼
Zongertinib: First Approval
Arnold Lee
11.首款获批：瑞米布替尼
Remibrutinib: First Approval
Simon Fung

七、药理学研究 (2026年第225卷)
Pharmacological Research
March 2026 - Volume 225（2026年3月第225卷）
https://www.sciencedirect.com/journal/pharmacological-research/vol/224/suppl/C

Review Articles（综述文章）
1.从气体递质到治疗新见解：揭示H₂S在NAFLD肠-肝轴中的作用
From gasotransmitter to therapeutic insight: Unraveling the role of H₂S in the gut-liver axis during NAFLD
Huimin Kang, Zhiyun Chen*
2.SAM-m⁶A轴作为植物源性疾病代谢调控的未开发治疗枢纽
The SAM-m⁶A axis as an unexplored therapeutic hub for plant-derived regulation of disease metabolism
Yuxuan Zhao, Hui Cao*
3.靶向FoxO1在心血管疾病中的机制与治疗潜力
Targeting FoxO1 in cardiovascular diseases: Mechanisms and therapeutic potential
Xue Wu, Chenxi Lu*
4.大麻素在年龄相关性疼痛中的治疗应用：当前证据与临床前景
Therapeutic use of cannabinoids in age-related pain: Current evidence and clinical perspectives
Sabina Pulone, Saverio Nucera*
5.TRPM2离子通道作为癌症、神经系统疾病和缺血/再灌注损伤潜在靶点的病理生理学意义
Pathophysiological significance of the TRPM2 ion channel as a potential target in cancer, neurological disorders, and ischemia/reperfusion injury
Sara Sultana, Wei Li*
6.Agrin在衰老十字路口：年龄相关疾病中的多效性调节因子
Agrin at the crossroads of aging: A pleiotropic regulator in age-related diseases
Jiayu Yuan, Xiaoyu Dong*
7.靶向SARM1-NAD⁺轴：逆转代谢疾病中能量与线粒体稳态失衡的新策略综述
Targeting the SARM1-NAD⁺ axis: A review of new strategy for reversing the imbalance of energy and mitochondrial homeostasis in metabolic diseases
Ao Xiong, Yue Zhang*
8.胃癌进展与化疗耐药的细胞因子表观遗传网络
Cytokine epigenetics network for gastric cancer progression and chemoresistance
Ganji Purnachandra Nagaraju, Bassel F. El-Rayes*
9.靶向Acod1/衣康酸在癌症治疗中的机制与机遇
Targeting Acod1/itaconate in cancer therapy: Mechanisms and opportunities
Tianlin Deng, Xiaodong Wu*
10.Pevonedistat靶向NEDD8活化酶治疗人类疾病：潜在机制、临床研究与未来方向
Pevonedistat targeting NEDDylation activating enzyme for human diseases: Underlying mechanisms, clinical studies, and future directions
Dong-Jun Fu, Ting Wang*
11.肠道菌群及其代谢产物在脑卒中中的作用：从机制研究到治疗前景
Gut microbiota and their metabolites in stroke: From mechanistic study toward therapeutic perspectives
Ao Shang, Jiangang Shen*
12.DCN型NEDD8 E3连接酶：结构、生物学功能与小分子抑制剂
DCN-type NEDD8 E3 ligases: Structure, biological function and small-molecule inhibitor
Wenjuan Zhou, Liying Ma*
13.大麻使用后尿液中Δ9-四氢大麻酚及其代谢产物浓度：系统综述
Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review
Danielle McCartney*
14.Seladelpar通过选择性PPAR-δ激活在原发性胆汁性胆管炎中临床疗效的机制原理
Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis
Alessio Gerussi*, Matteo Fornai*
Regular Articles（研究论文）
15.逍遥散和异甘草素重塑抑郁相关染色质三维结构与NF-κB p65相分离
Xiaoyaosan and isoliquiritigenin remodel depression-associated chromatin 3D structure and phase separation of NF-κB p65
Lili Fan*
16.SPG76遗传性痉挛性截瘫中的细胞凋亡与运动缺陷：钙蛋白酶2抑制作为治疗策略
Apoptosis and motor deficits in SPG76 hereditary spastic paraplegia: Calpain 2 inhibition as therapeutic strategy
Francesca Brivio, Chiara Vantaggiato*
17.Neuropilin-1作为IL-13的共受体重编程肝纤维化中的巨噬细胞
Neuropilin-1 acts as a co-receptor of IL-13 to reprogram macrophages in liver fibrosis
Chenxi Liu, Qiang Zhu*
18.用于治疗CD147阳性卵巢癌且毒性有限的多蛋白酶激活前体药物-抗体偶联物
Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity
Bo Wang, Sihe Zhang*
19.内皮细胞与全局METRNL的对比揭示内皮METRNL通过线粒体稳态抵抗动脉粥样硬化的重要性
Endothelial versus global METRNL reveals importance of endothelial METRNL against atherosclerosis via mitochondrial homeostasis
Dao-Xin Wang, Chao-Yu Miao*
20.白藜芦醇-硫化氢供体杂合物作为过敏性哮喘的多靶点治疗策略
A resveratrol–hydrogen sulfide donor hybrid as a multi-target therapeutic strategy for allergic asthma
Martina Simonelli, Fiorentina Roviezzo*
21.组蛋白H4赖氨酸5乳酸化：缺血性脑卒中期间小胶质细胞免疫代谢的关键调控因子
Histone H4 lysine 5 lactylation: A key regulator of immune metabolism in microglia during ischemic stroke
Yishan Li, Li Peng*
22.感觉神经元通过神经肽释放和κ-阿片反向调节介导疼痛信号驱动乳腺癌进展
Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and κ-opioid counter-regulation
Hitoshi Makabe, Minoru Narita*
23.紫檀芪通过抑制IL-6/STAT3-caspase-3/GSDME介导的心肌细胞焦亡和巨噬细胞M1极化减轻多柔比星诱导的心脏毒性
Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-caspase-3/GSDME axis and M1 polarization of macrophages
Xiaoxia Huang, Lin Li*
24.阻断CD93/IGFBP7相互作用的新型肽可正常化肿瘤血管并与放疗协同用于癌症免疫治疗
A novel peptide blocking CD93/IGFBP7 interaction normalizes tumor vessels and synergizes with radiotherapy for cancer immunotherapy
Yuzhen Qian, Lingling Li*
25.ZBTB16通过Pyrin炎症小体控制艰难梭菌结肠炎的发作
ZBTB16 controls the onset of Clostridium difficile colitis through the Pyrin inflammasome
Shuhui Li, Xuefeng Fei*
26.结肠炎中的肠-肝轴失调是中药结构依赖性药代动力学的基础
Gut-liver axis dysregulation in colitis underlies structure-dependent pharmacokinetics of a traditional Chinese medicine
Ka Wing Cheng, Zhaoxiang Bian*
27.长期咖啡因摄入通过减少海马神经炎症和增强神经元活性预防肥胖诱导的认知和记忆损伤
Chronic caffeine consumption prevents obesity-induced cognitive and memory impairments by reducing neuroinflammation and enhancing neuronal activity in the hippocampus
Adriana M. Capucho, Sílvia V. Conde*
28.调控代谢重编程的单核髓源性抑制细胞通过IL-10/HIF-1α/DLL4信号预防结肠炎相关异型增生
Manipulating metabolism-reprogrammed monocytic-MDSCs prevents colitis-associated dysplasia by IL-10/HIF-1α/DLL4 signaling
Yirui Wang, Xiaoyan Shen*
29.抑制Kdm2a与达米诺齐德通过表观遗传调控肠-眼轴抑制高度近视进展及相关神经精神共病
Inhibition of Kdm2a with Daminozide suppresses high myopia progression and related neuropsychiatric comorbidities by epigenetically modulating the gut-eye axis
Zixuan Li, Xiaomeng Ren*
30.司美格鲁肽通过塑造肠道菌群减轻BTBR小鼠的自闭症样行为
Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota
Jiayin Liu, Xiaotang Fan*
31.四种新型非规范氨基酸连接PSMA靶向PET放射性示踪剂的首次人体评估：比较研究
First-in-human evaluation of four novel PSMA-targeted PET radiotracers with non-canonical amino acid linkage: A comparative study
Dong Dai, Kuan Hu*
32.通过偶联胃泌素/胆囊收缩素B受体配体实现线粒体Kv1.3通道抑制剂的肿瘤特异性靶向，在原位模型中强烈减少胰腺导管腺癌
Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B receptor ligand strongly reduces pancreatic ductal adenocarcinoma in orthotopic models
Sofia Parrasia, Ildiko Szabo*
33.益生菌来源的细胞外囊泡通过肠-肝轴减轻胆汁淤积性肝损伤
Probiotic-derived extracellular vesicles attenuate cholestatic liver damage via gut-liver axis
Xianjiao Liu, Yunhuan Liu*
Letters to the Editor（读者来信）
34.对“血浆miR-150-5p作为乙酰胆碱受体阳性重症肌无力免疫抑制治疗反应的生物标志物：一项长期前瞻性纵向研究”的评论
Comment on "Plasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: A long-term prospective longitudinal study"
Shanshan Ru*
35.对读者来信的回复：Ru和Zhang关于“血浆miR-150-5p作为乙酰胆碱受体阳性重症肌无力免疫抑制治疗反应的生物标志物”一文的评论
Response to Letter to the Editor: Letter by Ru and Zhang regarding article, "Plasma miR-150–5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study"
Nemanja Garai, Dusanka Savic-Pavicevic*

八、抗病毒研究 (2026年第247卷)
Antiviral Research
March 2026 - Volume 247（2026年3月第247卷）
https://www.sciencedirect.com/journal/antiviral-research/vol/246/suppl/C

Research article（研究论文）
1.治疗性鼻内递送NanoSTING可提供针对季节性和高致病性流感毒株的广泛保护
Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains
Ankita Leekha, Navin Varadarajan*
2.拉帕醇（一种二氢乳清酸脱氢酶抑制剂）在体外和体内对猫杯状病毒具有抗病毒活性
Lapachol, a dihydroorotate dehydrogenase inhibitor, demonstrates antiviral activity against feline calicivirus in vitro and in vivo
Zexin Liu, Jianxin Chen*
3.HIV融合抑制剂Lipovirtide在非人灵长类动物中的药代动力学与安全性研究
Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primates
Yuanmei Zhu, Yuxian He*
4.SOX6是一种新型宿主因子，通过增强增强子I的转录活性促进乙型肝炎病毒复制
SOX6 is a novel host factor that promotes hepatitis B virus replication by enhancing the transcriptional activity of enhancer I
Yarong Song, Jie Wang*
5.克里米亚-刚果出血热中的靶向有机酸谱分析：基于代谢组学的生物标志物发现方法
Targeted organic acid profiling in Crimean-Congo hemorrhagic fever: A metabolomics-based approach to biomarker discovery
Halef Okan Doğan*
6.奥贝德西韦在COVID-19高风险非住院参与者中的3期BIRCH研究中的SARS-CoV-2耐药性分析
SARS-CoV-2 resistance analyses from the Phase 3 BIRCH study of obeldesivir in high-risk nonhospitalized participants with COVID-19
Charlotte Hedskog*
7.奥贝德西韦在COVID-19低风险非住院参与者中的3期OAKTREE研究中的SARS-CoV-2耐药性分析
SARS-CoV-2 resistance analyses from the Phase 3 OAKTREE study of obeldesivir in low-risk nonhospitalized participants with COVID-19
Lauren Rodriguez*
8.麻疹的急性期管理：治疗策略的系统综述
Acute management of measles: A systematic review of therapeutic strategies
Amandeep Kaur, Matthew Halma*
9.预防性鼻内给予细菌裂解物OM-85可减轻小鼠中人鼻病毒（RV-A1b）肺部感染和炎症
Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice
Sabine Wronski, Edouard Baulier*
10.基于烟酰胺的Sirtuin 2抑制剂作为抗人巨细胞病毒药物
Nicotinamide-based Sirtuin 2 inhibitors as anti-HCMV agents
Dariya Begum, Robert J. Geraghty*
11.马立克病病毒的UL23胸苷激酶是抗HSV药物开发的靶点
The UL23 thymidine kinase of Marek's disease virus is a target for anti-HSV drug development
Yunzhe Kang, Aijun Sun*
Review article（综述文章）
12.针对HBV的基因编辑策略综述
Overview of gene editing strategies against HBV
Zak T. Janetzki, Margaret Littlejohn*
13.戊型肝炎病毒的分子与细胞生物学及治疗机遇最新进展
Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities
Laura Corneillie, Laurence Cocquerel*
14.丙型肝炎病毒的消除：近在咫尺，还是遥不可及？
Hepatitis C virus elimination: So close, so far?
Jean-Michel Pawlotsky*

九、英国药理学杂志 (2026年第183卷第5-6期)
British Journal of Pharmacology
（一）March 2026 - Volume 183 - Issue 5（2026年3月第183卷第5期）
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2026/183/3

MINI REVIEW（微型综述）
1.CB2还是非CB2：重新审视急性和慢性肾损伤中的肾脏保护作用
To CB2 or not CB2: Revisiting renoprotection in acute and chronic kidney injury
Jonathan M. de Jesus, Bob M. Moore II*, Frank Park*
RESEARCH ARTICLE（研究论文）
2.利用ADAM10前结构域进行选择性抑制以促进心肌梗死后的恢复
Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction
Erik Klapproth*
3.京大戟糖鞘脂通过激活肠嗜铬细胞中的TRPA1破坏肠道运动与体液平衡
Euphorbia pekinensis glycosphingolipids disrupt gut motility and fluid balance via TRPA1 activation in enterochromaffin cells
Jie Cao, Hongli Yu*
4.深度学习增强的3D成像揭示司美格鲁肽对心脏纤维化的影响
Deep learning-enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis
Sheyla Barrado-Ballestero, Urmas Roostalu*
5.视黄酸结合蛋白2及其与岛叶皮层的相互作用对骨关节炎及相关焦虑样行为的调控
Regulation of osteoarthritis and associated anxiety-related behaviours by retinoic acid binding protein 2 and its interaction with the insular cortex
Yixuan Zhao, Wei Li*
6.人和豚鼠气道中的ATP释放与代谢及P2X受体依赖性对支气管肺迷走神经传入亚型的影响
ATP release and metabolism by human and guinea pig airways and P2X receptor-dependent effects on bronchopulmonary vagal afferent nerve subtypes
Brendan J. Canning*
7.CircPTK2通过稳定NFYA和上调FOXM1抑制细胞衰老，增强非小细胞肺癌增殖
CircPTK2 enhances non-small cell lung cancer proliferation by inhibiting cellular senescence through stabilizing NFYA and elevating FOXM1
Qiuhui Li, Xuefei Shi*
8.欧前胡素通过调节Suv39h1/Fabps/Cept1信号通路改善代谢功能障碍相关脂肪性肝病
Imperatorin ameliorates metabolic dysfunction-associated fatty liver disease through modulating Suv39h1/Fabps/Cept1 signalling pathway
Yi Sun, Huijun Sun*
9.马瓦卡姆滕在多种猪和人类肥厚型心肌病模型中的转录与功能效应
Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy
Elisa Kiselev, Thomas Thum*
10.大风子素D诱导的microRNA-145-5p下调SERPINE1并抑制卵巢癌转移
Hydnocarpin D-induced microRNA-145-5p down-regulates SERPINE1 and suppresses metastasis in ovarian cancer
Zhihui Zhu*
11.肠内酯增强吉西他滨对上皮性卵巢癌的疗效并改善肠道菌群失调
Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis
Danli Cao, Huidi Liu*
12.来特莫韦和更昔洛韦抑制耐药巨细胞病毒的机制研究
Mechanistic insights into the inhibition of drug-resistant cytomegalovirus by letermovir and ganciclovir
Noriaki Sato, Kimiyasu Shiraki*
13.远端外泌体中成纤维细胞特异性miRNA功能簇通过Rap1b/ERK1/2轴加重心肌缺血/再灌注损伤
A fibroblast-specific miRNA functional cluster in remote exosomes aggravates myocardial ischaemia/reperfusion injury via the Rap1b/ERK1/2 axis
Rui Zhang, Yulin Liao*

（二）March 2026 - Volume 183 - Issue 6 （2026年3月第183卷第6期）

https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2026/183/4

IMMUNOTHERAPY IN CANCER - EDITORIAL（癌症免疫治疗专题 - 卷首语）
1.癌症免疫治疗：新方法与未来展望
Immunotherapy in cancer: novel approaches and future perspectives
Barbara Stefanska*
IMMUNOTHERAPY IN CANCER - THEMED ISSUE REVIEW（癌症免疫治疗专题 - 专题综述）
2.膀胱癌器官保留疗法中整合新型免疫治疗方法的进展
Integrating novel immunotherapeutic approaches in organ-preserving therapies for bladder cancer
Éva Michaud, José Joao Mansure, Wassim Kassouf*
3.蛋白酪氨酸磷酸酶作为癌症免疫治疗的新兴靶点
Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
Zihan Qu, Jiajun Dong, Zhong-Yin Zhang*
4.Foxp3+调节性T细胞对肿瘤微环境中CD8+ T细胞功能障碍及免疫检查点抑制剂应答的影响
The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
Mikhaël Attias, Ciriaco A. Piccirillo*
5.免疫检查点抑制剂相关免疫不良事件的治疗选择
Treatment options for immune-related adverse events associated with immune checkpoint inhibitors
Yu Hua Chen*
IMMUNOTHERAPY IN CANCER - THEMED ISSUE ARTICLE（癌症免疫治疗专题 - 专题研究论文）
6.抗组织蛋白酶D免疫疗法触发乳腺癌中的先天性和适应性抗肿瘤免疫
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer
Timothée David, Emmanuelle Liaudet-Coopman*

十、临床药代动力学 (2026年第65卷第3期)
Clinical Pharmacokinetics
March 2026 -Volume 65 - Issue 3（2026年3月第65卷第3期）
https://link.springer.com/journal/40262/volumes-and-issues/65-2

Review Article（综述文章）
1.肥胖成人中的β-内酰胺类抗生素：群体药代动力学分析综述
β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses
Guiva Annane*
Original Research Article（原创研究）
2.非肽类促性腺激素释放激素拮抗剂Merigolix的药代动力学-药效学建模与模拟
Pharmacokinetic–Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist
Soo Hyeon Bae, Sungpil Han*
3.接受机械循环支持装置植入的成年患者静脉注射氟康唑的药代动力学分析
A Pharmacokinetic Analysis of Intravenous Fluconazole in Adult Patients Undergoing Mechanical Circulatory Support Device Implantation
Kelly A. Cairns*
4.人工关节感染患者血浆和骨组织中静脉注射头孢呋辛的群体药代动力学：剂量优化是否有空间？
Population Pharmacokinetics of Intravenous Cefuroxime in Plasma and Bone of Patients with Prosthetic Joint Infection: Is There Room for Dose Optimization?
Gerbert Coen de Waard,  Birgit C. P. Koch*
5.支持长效胰岛素类似物摩尔剂量比确定的群体药代动力学与药效学建模
Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs
Dan Tang, Sheng Feng*
6.卡博替尼与清淡早餐同服的影响：一项随机交叉药代动力学研究（SKIPPY 1）
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)
Amy Rieborn, Dirk Jan A.R. Moes*
7.布仑索卡替单次剂量在肝功能不全受试者和肝功能正常匹配受试者中的药代动力学与安全性
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions
Helen Usansky*
8.使用碘海醇群体药代动力学建模方法准确估算危重症婴幼儿的肾小球滤过率
Accurate Estimation of Glomerular Filtration Rate in Critically Ill Infants and Children Using a Iohexol Population Pharmacokinetic Modeling Approach
Evelyn Dhont*
9.在淋巴瘤成年患者甲氨蝶呤清除率群体药代动力学模型中使用基于胱抑素C的GFR方程
Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma
Zachary L. Taylor*
10.霉酚酸药代动力学研究：对肾移植受者肠肝循环的新见解
A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients
Moataz E. Mohamed, Pamala A. Jacobson*